Sugi Predict

Sugi Predict / Compounds / SCHEMBL1022965

SCHEMBL1022965

SCHEMBL1022965

COC(=O)c1ccc(-n2ccnc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 1.00
▸ CYP3A4 P08684 1/20 0.69
▸ BAZ2B Q9UIF8 1/20 0.69
▸ MAPT P10636 4/20 0.63
▸ LMNA P02545 2/20 0.63
▸ ADH5 P11766 2/20 0.60
▸ HTR2A P28223 1/20 0.57
▸ HTR2C P28335 1/20 0.57
▸ HTR2B P41595 1/20 0.57
▸ ENPP2 Q13822 1/20 0.54
▸ MKNK1 Q9BUB5 1/20 0.54
▸ MKNK2 Q9HBH9 1/20 0.54
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ TDP1 Q9NUW8 1/20 0.53
▸ MAOB P27338 2/20 0.52
▸ PDE4A P27815 1/20 0.52
▸ PDE4B Q07343 1/20 0.52
▸ PDE4C Q08493 1/20 0.52
▸ PDE4D Q08499 1/20 0.52
▸ MAPK8 P45983 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25252559 0.86 HTT (0.74) HTTCYP3A4BAZ2BMAPTLMNA
SCHEMBL25740983 0.85 HTT (0.72) HTTCYP3A4BAZ2BMAPTLMNA
SCHEMBL476250 0.84 HTT (0.72) HTTCYP3A4BAZ2BMAPTLMNA
SCHEMBL10480632 0.83 HTT (0.71) HTTCYP3A4BAZ2BMAPTLMNA
SCHEMBL6536350 0.83 HTT (0.71) HTTCYP3A4BAZ2BMAPTLMNA
SCHEMBL5800533 0.83 HTT (0.71) HTTCYP3A4BAZ2BMAPTLMNA
SCHEMBL17629891 0.82 HTT (0.68) HTTCYP3A4BAZ2BMAPTLMNA
Hydrochloric Acid SCHEMBL28276875 0.82 HTT (0.69) HTTCYP3A4BAZ2BMAPTLMNA
SCHEMBL28274825 0.82 HTT (0.69) HTTCYP3A4BAZ2BMAPTLMNA
SCHEMBL7289319 0.82 HTT (0.69) HTTCYP3A4BAZ2BMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103193571-A Copper salt catalyzing system UNIV SOOCHOW 2013-07-10 — — CN disclosed
US-8384068-B2 Use of acridine derivatives as matrix materials and/or electron blockers in OLEDs BASF SE (DE) 2013-02-26 — — US disclosed
EP-2195868-B1 USE OF ACRIDINE DERIVATIVES AS MATRIX MATERIALS AND/OR AN ELECTRON BLOCKER IN OLEDS BASF SE (DE) 2013-01-02 — — EP disclosed
US-7989091-B2 Silanes containing phenothiazine-S-oxide or phenothiazine-S,S-dioxide groups and the use thereof in OLEDs BASF SE (DE) 2011-08-02 — — US disclosed
EP-2150556-B1 SILANES CONTAINING PHENOTHIAZINE-S-OXIDE OR PHENOTHIAZINE-S,S-DIOXIDE GROUPS AND THE USE THEREOF IN OLEDS BASF SE (DE) 2011-01-12 — — EP disclosed
US-20100219406-A1 USE OF ACRIDINE DERIVATIVES AS MATRIX MATERIALS AND/OR ELECTRON BLOCKERS IN OLEDS BASF SE (DE) 2010-09-02 — — US disclosed
US-20100187980-A1 SILANES CONTAINING PHENOTHIAZINE-S-OXIDE OR PHENOTHIAZINE-S,S-DIOXIDE GROUPS AND THE USE THEREOF IN OLEDS BASF SE (DE) 2010-07-29 — — US disclosed
EP-2195868-A1 USE OF ACRIDINE DERIVATIVES AS MATRIX MATERIALS AND/OR AN ELECTRON BLOCKER IN OLEDS Basf Se (DE) 2010-06-16 — — EP disclosed
EP-2150556-A1 SILANES CONTAINING PHENOTHIAZINE-S-OXIDE OR PHENOTHIAZINE-S,S-DIOXIDE GROUPS AND THE USE THEREOF IN OLEDS BASF SE (DE) 2010-02-10 — — EP disclosed
EP-2085086-A2 Method for treating congestive heart failure or diabetic nephropathy Synvista Therapeutics, Inc. (US) 2009-08-05 — — EP disclosed
CN-1053613-A Nitrogen-containing spiro ring MERCK & CO INC (US) 1991-08-07 — — CN disclosed
EP-0431943-A2 Nitrogen-containing spirocycles MERCK & CO. INC. (US) 1991-06-12 — — EP disclosed
EP-0358284-A2 Derivatized alkanolamines as cardiovascular agents SCHERING AKTIENGESELLSCHAFT (DE) 1990-03-14 — — EP disclosed
EP-0169164-B1 IMIDAZOLONECARBONYLARYLIMIDAZOLES; METHOD OF MANUFACTURE, METHOD OF USE AND COMPOSITIONS USEFUL THEREOF SCHERING AKTIENGESELLSCHAFT (DE) 1990-01-31 — — EP disclosed
WO-1990000548-A2 DERIVATIZED ALKANOLAMINES AS CARDIOVASCULAR AGENTS SCHERING AKTIENGESELLSCHAFT BERLIN AND BERGKAMEN (DE) 1990-01-25 — — WO disclosed
US-4804662-A Substituted 4-(1H-imidazol-1-yl)benzamides as antiarrhythmic agents SCHERING A.G. (DE) 1989-02-14 — — US disclosed
EP-0290377-A1 Substituted 4-[1H-Imidazol-1-yl] benzamides as antiarrhythmic agents SCHERING AKTIENGESELLSCHAFT (DE) 1988-11-09 — — EP disclosed
US-4709043-A Process for the preparation of imidazolonecarbonylarylimidazoles SCHERING A.G. (DE) 1987-11-24 — — US disclosed
EP-0169164-A1 Imidazolonecarbonylarylimidazoles; method of manufacture, method of use and compositions useful thereof SCHERING AKTIENGESELLSCHAFT (DE) 1986-01-22 — — EP disclosed
US-4556665-A Cardiotonic 1,3-dihydro-4-[[(imidazol-1-yl)aryl]carbonyl]imidazol-2-ones SCHERING A.G. (DE) 1985-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100187980-A1 SILANES CONTAINING PHENOTHIAZINE-S-OXIDE OR PHENOTHIAZINE-S,S-DIOXIDE GROUPS AND THE USE THEREOF IN OLEDS OPRD1, PPID, PLOD2 HTT 137/4885CYP3A4 243/4885BAZ2B 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.